Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Strikes Deals With Vernalis, Nabi

by Michael McCoy
August 17, 2009 | A version of this story appeared in Volume 87, Issue 33

GlaxoSmithKline will collaborate with Vernalis to develop drugs that act against an undisclosed oncology target. Under the deal, Vernalis will receive $6 million up front and could get milestone payments exceeding $200 million. Vernalis will apply its structure-based drug-design technique to advance small-molecule drug candidates. Separately, GSK has acquired Nabi Pharmaceuticals’ PentaStaph for up to $45 million. PentaStaph is a vaccine being developed against Staphylococcus aureus, a multi-drug-resistant bacterium.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.